Radioiodinated Bicyclic RGD Peptide Derivatives for Enhanced Tumor Accumulation

<b>Background/Objectives</b>: Integrin α<sub>V</sub>β<sub>3</sub> plays a crucial role in tumor angiogenesis and cancer progression, making it a key target for radiolabeled probes used in imaging and therapy. A previously developed probe, [<sup>125</sup>I]bcRGD, exhibited high selectivity for α<sub>V</sub>β<sub>3</sub> but limited tumor accumulation due to rapid blood clearance. This study aimed to address this issue through two strategies: (1) conjugating albumin-binding molecules to enhance systemic circulation and (2) dimerizing RGD peptides to improve binding affinity via multivalency effects. <b>Methods</b>: Three [<sup>125</sup>I]bcRGD derivatives were synthesized: [<sup>125</sup>I]bcRGD<sub>pal</sub> (with palmitic acid), [<sup>125</sup>I]bcRGD<sub>iba</sub> (with 4-(<i>p</i>-iodophenyl)butyric acid), and [<sup>125</sup>I]bcRGD<sub>dimer</sub> (a dimeric bicyclic RGD peptide). Their physicochemical properties, α<sub>V</sub>β<sub>3</sub>-selectivity, albumin-binding capacity, and biodistribution were assessed in vitro and in vivo using tumor-bearing mice. Tumor models included α<sub>V</sub>β<sub>3</sub>-high U-87 MG and α<sub>V</sub>β<sub>3</sub>-low A549 xenografts. <b>Results</b>: [<sup>125</sup>I]bcRGD<sub>pal</sub> and [<sup>125</sup>I]bcRGD<sub>iba</sub> exhibited prolonged blood retention (30-fold and 55-fold vs. [<sup>125</sup>I]bcRGD, respectively) and increased tumor accumulation (3.9% ID/g and 3.6% ID/g at 2 h, respectively). Despite improved systemic circulation, tumor-to-blood ratios remained low (<1), indicating limited tumor retention. [<sup>125</sup>I]bcRGD<sub>dimer</sub> achieved significantly greater tumor accumulation (4.2% ID/g at 2 h) and favorable tumor-to-blood (22) and tumor-to-muscle (14) ratios, with a 5.4-fold higher uptake in U-87 MG tumors compared to A549 tumors. <b>Conclusions</b>: Dimerization was more effective than albumin binding in enhancing bcRGD's tumor-targeting potential. The dimeric probe demonstrated improved tumor accumulation, favorable pharmacokinetics, and preserved integrin selectivity. These findings provide a foundation for further structural optimization of bicyclic RGD peptides for integrin α<sub>V</sub>β<sub>3</sub>-targeted imaging and therapy applications.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2025-04-08
DOI
https://doi.org/10.3390/ph18040549
Citations
4
Primary Topic
Cell Adhesion Molecules Research
Type
article
Field-Weighted Citation Impact
6.49

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Radioiodinated Bicyclic RGD Peptide Derivatives for Enhanced Tumor Accumulation

Fuko Hirano, Takashi Temma, Naoya Kondo, M. Kato et al.
4 citations
Pharmaceuticals
Cell Adhesion Molecules Research
6.49
article

Radioiodinated Bicyclic RGD Peptide Derivatives for Enhanced Tumor Accumulation

Fuko Hirano, Takashi Temma, Naoya Kondo, M. Kato, Akio Oshima, A. Miyazaki
article en
4 citations

Abstract

<b>Background/Objectives</b>: Integrin α<sub>V</sub>β<sub>3</sub> plays a crucial role in tumor angiogenesis and cancer progression, making it a key target for radiolabeled probes used in imaging and therapy. A previously developed probe, [<sup>125</sup>I]bcRGD, exhibited high selectivity for α<sub>V</sub>β<sub>3</sub> but limited tumor accumulation due to rapid blood clearance. This study aimed to address this issue through two strategies: (1) conjugating albumin-binding molecules to enhance systemic circulation and (2) dimerizing RGD peptides to improve binding affinity via multivalency effects. <b>Methods</b>: Three [<sup>125</sup>I]bcRGD derivatives were synthesized: [<sup>125</sup>I]bcRGD<sub>pal</sub> (with palmitic acid), [<sup>125</sup>I]bcRGD<sub>iba</sub> (with 4-(<i>p</i>-iodophenyl)butyric acid), and [<sup>125</sup>I]bcRGD<sub>dimer</sub> (a dimeric bicyclic RGD peptide). Their physicochemical properties, α<sub>V</sub>β<sub>3</sub>-selectivity, albumin-binding capacity, and biodistribution were assessed in vitro and in vivo using tumor-bearing mice. Tumor models included α<sub>V</sub>β<sub>3</sub>-high U-87 MG and α<sub>V</sub>β<sub>3</sub>-low A549 xenografts. <b>Results</b>: [<sup>125</sup>I]bcRGD<sub>pal</sub> and [<sup>125</sup>I]bcRGD<sub>iba</sub> exhibited prolonged blood retention (30-fold and 55-fold vs. [<sup>125</sup>I]bcRGD, respectively) and increased tumor accumulation (3.9% ID/g and 3.6% ID/g at 2 h, respectively). Despite improved systemic circulation, tumor-to-blood ratios remained low (<1), indicating limited tumor retention. [<sup>125</sup>I]bcRGD<sub>dimer</sub> achieved significantly greater tumor accumulation (4.2% ID/g at 2 h) and favorable tumor-to-blood (22) and tumor-to-muscle (14) ratios, with a 5.4-fold higher uptake in U-87 MG tumors compared to A549 tumors. <b>Conclusions</b>: Dimerization was more effective than albumin binding in enhancing bcRGD's tumor-targeting potential. The dimeric probe demonstrated improved tumor accumulation, favorable pharmacokinetics, and preserved integrin selectivity. These findings provide a foundation for further structural optimization of bicyclic RGD peptides for integrin α<sub>V</sub>β<sub>3</sub>-targeted imaging and therapy applications.

PharmaceuticalsVol. 18(4)
Kansai Medical University (JP), Osaka University of Pharmaceutical Sciences (JP)
Japan Society for the Promotion of Science
Good health and well-being
Openalex Percentile: Top 4%
Cell Adhesion Molecules Research
6.49
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.